Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed this Form 8-K on April 27, 2026, regarding its listing status on the Nasdaq Global Select Market. The Company is incorporated in Delaware and headquartered in South San Francisco, California.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance matters related to stock listing requirements.
Material Changes
- Regained Bid Price Compliance: The Company received notification from Nasdaq that it has regained compliance with the minimum bid price requirement (Listing Rule 5450(a)(1)). The closing bid price was at least $1.00 per share for 10 consecutive business days from April 13, 2026, through April 24, 2026.
- Ongoing MVLS Non-Compliance: The Company remains non-compliant with the Market Value of Listed Securities (MVLS) requirement (Listing Rule 5450(b)(2)(A)), which mandates a minimum value of $50,000,000.
Outlook, Risks, and Contingencies
- Compliance Deadline: The Company has 180 calendar days, until September 14, 2026, to regain compliance with the MVLS Requirement.
- Delisting Risk: Management states there can be no assurance that the Company will be able to regain compliance with the MVLS Requirement or maintain compliance with other applicable Nasdaq listing requirements.
- Resolution Status: Nasdaq has closed the matter regarding the minimum bid price requirement.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess the gap against the $50,000,000 threshold.
- Monitor the stock price to ensure it remains above the $1.00 minimum bid price to avoid renewed non-compliance.
- Review upcoming filings for any announcements regarding capital raises or strategic actions intended to meet the September 14, 2026, MVLS deadline.